We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-22.73%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.29B
AUM Growth
-$508M
Cap. Flow
-$29.9M
Cap. Flow %
-2.32%
Top 10 Hldgs %
71.19%
Holding
44
New
1
Increased
10
Reduced
7
Closed
–

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.6M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$2.35M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$1.67M
4
ENDP
Endo International plc
ENDP
+$1.29M
5
WMGI
Wright Medical Group Inc
WMGI
+$1.09M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$47.6M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$1.83M
3
STAA icon
STAAR Surgical
STAA
+$168K
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$107K
5
EPZM
Epizyme, Inc
EPZM
+$55.6K

Sector Composition

Rank Sector Weight
1 Healthcare 81.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIGL icon
26
Rigel Pharmaceuticals
RIGL
$782M
$10.9M 0.84%
523,092
-820
-0.2% -$20.2K
HTWR
27
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$7.91M 0.61%
251,868
+5,800
+2% +$196K
ALIM
28
DELISTED
Alimera Sciences
ALIM
$5.27M 0.41%
200,920
– –
AIMT
29
DELISTED
Aimmune Therapeutics
AIMT
$4.42M 0.34%
325,599
– –
TLPH icon
30
Talphera
TLPH
$72.7M
$4.39M 0.34%
71,272
– –
VIRX
31
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.77M 0.29%
33,214
– –
EXAS
32
DELISTED
Exact Sciences
EXAS
$2.67M 0.21%
396,276
– –
ACGN
33
DELISTED
Aceragen Inc
ACGN
$2.49M 0.19%
9,257
– –
ALGN icon
34
Align Technology
ALGN
$12.4B
$2.02M 0.16%
27,757
– –
PGEN icon
35
Precigen
PGEN
$2.45B
$1.6M 0.12%
47,524
– –
DRNA
36
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.44M 0.11%
267,890
– –
OCGN icon
37
Ocugen
OCGN
$475M
$1.04M 0.08%
7,576
– –
ARCT icon
38
Arcturus Therapeutics
ARCT
$216M
$963K 0.07%
36,313
– –
OREX
39
DELISTED
Orexigen Therapeutics, Inc.
OREX
$941K 0.07%
167,302
– –
CYTK icon
40
Cytokinetics
CYTK
$10.5B
$872K 0.07%
123,686
– –
SPHS
41
DELISTED
Sophiris Bio, Inc.
SPHS
$711K 0.06%
494,000
– –
MRNS
42
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$318K 0.02%
14,754
– –
ZGNX
43
DELISTED
Zogenix, Inc.
ZGNX
$264K 0.02%
28,600
– –
QURE icon
44
uniQure
QURE
$3.13B
$243K 0.02%
20,453
– –
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q1 2016 Portfolio in Review

As of Q1 2016, Palo Alto Investors held 44 positions worth $1.29B, down 28% from $1.8B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Trading was light in Q1 2016: portfolio turnover was 2.3%. Palo Alto Investors opened 1 new position and made no exits, leaving the 44-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 78% a quarter earlier.

  • Palo Alto Investors's largest Q1 2016 buy was Acadia Pharmaceuticals: 485,100 shares worth $13.6M.
  • Palo Alto Investors added most to ANACOR PHARMACEUTICALS INC COM in Q1 2016, an estimated $2.35M increase.
  • Palo Alto Investors's biggest Q1 2016 reduction was Abiomed Inc, cutting an estimated $47.6M.
  • Palo Alto Investors's ten largest holdings make up 71% of its $1.29B portfolio in Q1 2016.
  • Palo Alto Investors opened 1 new position and closed 0 in Q1 2016.
  • Palo Alto Investors's portfolio value fell 28% quarter-over-quarter to $1.29B.

Based on Palo Alto Investors's 13F filing for Q1 2016, filed 16 May 2016.